Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Divergent roles of crassifolin B and cyperenoic acid from Gentiana kurroo in regulating adipocyte differentiation in 3T3-L1 cells through PPARγ and MAPK pathways.

Nishina A., Sato D., Udagawa T., Ninomiya M., Koketsu M., Kimura H.

Animal Study on Systemic / IV, published in J Ethnopharmacol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
J Ethnopharmacol (2025)
Country
Ireland
Reported sample size
—
Source database
PubMed
PMID
41274520
DOI
10.1016/j.jep.2025.120923

Abstract (original English)

Gentiana kurroo Royle (Gentianaceae) is a traditional medicinal plant native to the northwestern Himalayas and is used in folk medicine to treat inflammation, gastrointestinal disorders, and metabolic diseases such as diabetes and obesity. However, scientific evidence on its bioactive constituents and their molecular mechanisms in regulating adipocyte function remains limited. To isolate and identify bioactive compounds from the stem extract of G. kurroo and evaluate their effects on adipocyte differentiation in 3T3-L1 cells, with particular focus on PPARγ and MAPK signaling pathways. Methanolic stem extracts of G. kurroo were fractionated, and the ethyl acetate fraction was subjected to MPLC for compound isolation. Six compounds were identified via spectral analysis. 3T3-L1 preadipocytes were treated with these compounds, and lipid accumulation was quantified. Western blotting was used to analyze protein expression of adipogenic and lipolytic markers. Inhibitor assays and molecular docking were employed to elucidate the signaling mechanisms. Among the isolated six compounds [crassifolin B (1), crassifolin L (2), chettaphanin I (3), cyperenoic acid (4), Teucvidin (5), and methyl 9-(furan-3-yl)-2,7,13-trimethyl-4-oxo-10-oxatricyclo[5.3.3.01,6]trideca-5,8-diene-2-carboxylate (6)], crassifolin B (compound (1) significantly promoted lipid accumulation and upregulated PPARγ, C/EBPα,

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Animals3T3-L1 CellsMicePPAR gammaAdipocytesMAP Kinase Signaling SystemPlant ExtractsAdipogenesisCell DifferentiationMolecular Docking Simulation

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research